| Predicate |
Object |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-445
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-075
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-451
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-435
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-353
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-453 |
| filingDate |
2001-09-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3d54e60383d6b904d96194123b3049af
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e86f2283d73b75e1d432343020b6d334
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_20bbac0a2175fed68dcd79b30dd331b4 |
| publicationDate |
2002-04-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2002045656-A1 |
| titleOfInvention |
Pharmaceutical combinations for the treatment of stroke and traumatic brain injury |
| abstract |
This invention relates to methods of treating traumatic brain injury (TBI) or hypoxic or ischemic stroke, comprising administering to a patient in need of such treatment an NR2B subtype selective N-methyl-D-aspartate (NMDA) receptor antagonist in combination with either: (a) a neutrophil inhibitory factor (NIF); (b) a sodium channel antagonist; (c) a nitric oxide synthase (NOS) inhibitor; (d) a glycine site antagonist; (e) a potassium channel opener; (f) an AMPA/kainate receptor antagonist; (g) a calcium channel antagonist; (h) a GABA-A receptor modulator (e.g., a GABA-A receptor agonist); or (i) an antiinflammatory agent. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9732037-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014138460-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10167260-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9416106-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9951014-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009170901-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9120750-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023133230-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10759791-B2 |
| priorityDate |
2000-09-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |